Back to discover
Disease
Graves' Disease
Late-stage therapeutic developmentEmerging research
2
Publications
13
Clinical trials
2024
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
The genetics of Graves' disease.
Research2023-12-18Reviews in endocrine & metabolic disorders
Thyroid-Gut-Axis: How Does the Microbiota Influence Thyroid Function?
Research2020-06-12Nutrients
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 4 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
- Q1 2027Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease: A Pilot Feasibility Trial
- Q1 2028A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' Disease
- Q2 2028A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
- Q3 2028A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' Disease
Major developments
Upcoming trial readoutHigh impact
Results expected Q1 20282026-07-30
Upcoming trial readoutHigh impact
Results expected Q2 20282026-07-08
Clinical MilestonesViewHide
Results expected
- 2026-07-30A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' DiseaseResults expected Q1 2028
- 2026-07-08A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid DrugsResults expected Q2 2028
- 2026-07-01A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' DiseaseResults expected Q3 2028
- 2026-01-27Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease: A Pilot Feasibility TrialResults expected Q1 2027
Recently completed
- 2026-06-30Randomized Controlled Trial of Preoperative Corticosteroids in Autoimmune ThyroidDiseasePrimary completion
Activity timeline5
- 2026-07-30ClinicalA Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' DiseaseResults expected Q1 2028
- 2026-07-08ClinicalA Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid DrugsResults expected Q2 2028
- 2026-07-01ClinicalA Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' DiseaseResults expected Q3 2028
- 2026-06-30ClinicalRandomized Controlled Trial of Preoperative Corticosteroids in Autoimmune ThyroidDiseasePrimary completion
- 2026-01-27ClinicalImpact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease: A Pilot Feasibility TrialResults expected Q1 2027
Clinical trials
The current development programme across all trial phases.
Clinical programme
13
6
9
6
Late-stage studies
Recruiting
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20202024
Most influential
Major themes3
- Gastrointestinal Microbiome1
- Graves Disease1
- Graves Ophthalmopathy1
Leading journals2
- Nutrients1
- Reviews in endocrine & metabolic disorders1
Leading researchers7
- Amrein K1
- Grixti L1
- Knezevic J1
- Lane LC1
- Pearce SH1
- Starchl C1
- Tmava Berisha A1
Affiliations (unnormalised)4
- Medical University of Graz1
- Royal Victoria Infirmary1
- The Great North Children's Hospital1
- Translational and Clinical Research Institute1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.